Evidence map›Paper›PMID 39491410›Full record

ArticleNeoplasia (New York, N.Y.)2023

Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center.

Jens von der Grün, Maiwand Ahmadsei, Isabel Breyer, Christian Britschgi, Daniel Eberli, Thomas Hermanns, Joanna Mangana, Henrik Petrowsky, Egle Ramelyte, Patrick Roth and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jens von der GrünDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland. Electronic address: Jens.vonderGruen@usz.ch.
Maiwand AhmadseiDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Isabel BreyerComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Gynecology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Christian BritschgiComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Daniel EberliComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Urology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Thomas HermannsComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Urology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Joanna ManganaComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Henrik PetrowskyComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Surgery and Transplantation, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Egle RamelyteComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Patrick RothComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Neurology & Brain Tumor Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Gabriel SchärComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Gynecology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Isabelle OpitzComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Thoracic Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Michael WellerComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Neurology & Brain Tumor Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Andreas WickiComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Isabell WitzelComprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Gynecology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Panagiotis BalermpasDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeTo analyze clinical trial activities and patient recruitment numbers into prospective clinical studies for solid malignancies during the COVID-19 pandemic in a tertiary cancer center. MATERIALS AND

methodsPatient recruitment numbers in prospective clinical studies of solid malignancies were retrospectively analyzed for the years 2019 - 2021 at the Comprehensive Cancer Center Zurich (CCCZ). Changes in recruitment numbers were tested for association with organ-specific subunits, as well as organizational and treatment-related trial characteristics. To assess differences between categorical variables, Chi-squared test was used. For uni- and multivariate analysis, Cox proportional hazards were calculated.

resultsIn 2019, there were a total of 107 studies (registry trials, clinical phase I-III trials, and translational studies) recruiting 304 patients at the CCCZ. During the COVID-19 pandemic in 2020 and 2021, there were 120 and 125 active trials with a total recruitment of 355 and 666 patients, respectively. No significant differences between the subunits and study characteristics in changes of patient recruitment in clinical phase I-III trials were identified when the year prior to the COVID-19 pandemic (2019) was compared to the first year of the pandemic (2020) and to 2020-2021.

conclusionsDespite healthcare systems around the world have experienced significant disruption due to the COVID-19 pandemic, data from our tertiary cancer center showed that clinical trial activities were maintained at a high level during the pandemic.

Indexed as

COVID-19OncologySolid tumorsTertiary cancer centerTrial recruitment

Identifiers

PMID39491410
PMCPMC10630114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.